Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.

Analysis of the chronic lymphocytic leukemia (CLL) coding genome has recently disclosed that the NOTCH1 proto-oncogene is recurrently mutated at CLL presentation. Here, we assessed the prognostic role of NOTCH1 mutations in CLL. Two series of newly diagnosed CLL were used as training (n = 309) and validation (n = 230) cohorts. NOTCH1 mutations occurred in 11.0% and 11.3% CLL of the training and validation series, respectively. In the training series, NOTCH1 mutations led to a 3.77-fold increase in the hazard of death and to shorter overall survival (OS; P < .001). Multivariate analysis selected NOTCH1 mutations as an independent predictor of OS after controlling for confounding clinical and biologic variables. The independent prognostic value of NOTCH1 mutations was externally confirmed in the validation series. The poor prognosis conferred by NOTCH1 mutations was attributable, at least in part, to shorter treatment-free survival and higher risk of Richter transformation. Although NOTCH1 mutated patients were devoid of TP53 disruption in more than 90% cases in both training and validation series, the OS predicted by NOTCH1 mutations was similar to that of TP53 mutated/deleted CLL. NOTCH1 mutations are an independent predictor of CLL OS, tend to be mutually exclusive with TP53 abnormalities, and identify cases with a dismal prognosis.

[1]  Š. Pospíšilová,et al.  Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. , 2009, Blood.

[2]  K. Maloum,et al.  Chlorambucil in Indolent Chronic Lymphocytic Leukemia , 1998 .

[3]  J. Aster,et al.  Notch signalling in T‐cell lymphoblastic leukaemia/lymphoma and other haematological malignancies , 2011, The Journal of pathology.

[4]  Axel Benner,et al.  Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. , 2008, Blood.

[5]  ONSTANZE,et al.  GENOMIC ABERRATIONS AND SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA , 2010 .

[6]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Michael Schemper,et al.  The explained variation in proportional hazards regression , 1990 .

[8]  I. Screpanti,et al.  Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. , 2009, Blood.

[9]  D. Rossi,et al.  Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia , 2011, Hematological oncology.

[10]  D C Case,et al.  Clinical staging of chronic lymphocytic leukemia. , 1977, The Journal of the Maine Medical Association.

[11]  A. Pettitt,et al.  The role of prognostic factors in assessing ‘high-risk’ subgroups of patients with chronic lymphocytic leukemia , 2007, Leukemia.

[12]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[13]  A. Ng,et al.  Diffuse large B-cell lymphoma. , 2007, Seminars in radiation oncology.

[14]  E. Steyerberg,et al.  [Regression modeling strategies]. , 2011, Revista espanola de cardiologia.

[15]  E. Montserrat,et al.  Natural history of chronic lymphocytic leukemia: on the progression and progression and prognosis of early clinical stages. , 1988, Nouvelle revue francaise d'hematologie.

[16]  C. C. Chen,et al.  The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model. , 1985, Statistics in medicine.

[17]  L. Pasqualucci,et al.  Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation , 2011, The Journal of experimental medicine.

[18]  S. Pileri,et al.  The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. , 2011, Blood.

[19]  A. Ferrando,et al.  Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. , 2011, Blood reviews.

[20]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[21]  D. Rossi,et al.  Richter syndrome: molecular insights and clinical perspectives , 2009, Hematological oncology.

[22]  P. Grambsch,et al.  Martingale-based residuals for survival models , 1990 .

[23]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[24]  I. Screpanti,et al.  NOTCH1 PEST domain mutation is an adverse prognostic factor in B‐CLL , 2010, British journal of haematology.

[25]  L. Medeiros,et al.  Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma , 2013 .

[26]  K. Maloum,et al.  Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. , 1998, The New England journal of medicine.

[27]  D. Rossi,et al.  The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness , 2009, Clinical Cancer Research.

[28]  F. Mancini,et al.  White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia , 2011, Haematologica.

[29]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[30]  References , 1971 .

[31]  E. Montserrat,et al.  Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. , 2005, Blood.

[32]  S. Stilgenbauer,et al.  Understanding and managing ultra high-risk chronic lymphocytic leukemia. , 2010, Hematology. American Society of Hematology. Education Program.

[33]  Andrew P. Weng,et al.  Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.

[34]  J F Lawless,et al.  Regression and recursive partition strategies in the analysis of medical survival data. , 1988, Journal of clinical epidemiology.

[35]  Daniel B. Mark,et al.  TUTORIAL IN BIOSTATISTICS MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS , 1996 .

[36]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[37]  E. Kimby,et al.  Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus , 2007, Leukemia.

[38]  Deborah A. Bowen,et al.  Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia , 2010, Cancer.

[39]  E. Giné,et al.  Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. , 2009, Blood.

[40]  T. Haferlach,et al.  The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype , 2009, Leukemia.

[41]  D.,et al.  Regression Models and Life-Tables , 2022 .

[42]  M. Hallek,et al.  Prognostic factors in chronic lymphocytic leukemia—what do we need to know? , 2011, Nature Reviews Clinical Oncology.

[43]  W. Grody,et al.  [Diffuse large B-cell lymphoma]. , 2006 .

[44]  David A. Schoenfeld,et al.  Partial residuals for the proportional hazards regression model , 1982 .

[45]  N. Chiorazzi,et al.  mechanisms of disease Chronic Lymphocytic Leukemia , 2010 .

[46]  Susan Slager,et al.  Validation of a new prognostic index for patients with chronic lymphocytic leukemia , 2009, Cancer.

[47]  Francesco Bertoni,et al.  Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome , 2009, Clinical Cancer Research.

[48]  A Benner,et al.  p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. , 1995, Blood.

[49]  T. Hamblin,et al.  Chronic lymphocytic leukaemia , 2008, The Lancet.

[50]  Natural history of stage A chronic lymphocytic leukaemia untreated patients , 1990, British journal of haematology.

[51]  A. Tsimberidou,et al.  Richter syndrome , 2005, Cancer.

[52]  J. C. van Houwelingen,et al.  Predictive value of statistical models , 1990 .

[53]  A. Favero,et al.  Using teicoplanin for empiric therapy of febrile neutropenic patients with haematological malignancies , 1990, British journal of haematology.

[54]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[55]  Kim-Anh Do,et al.  Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. , 2007, Blood.

[56]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.